The fore­cast for biotech IPOs in 2017? Not near­ly as hot as the in­dus­try would like


Last year on­ly 28 bio­phar­ma com­pa­nies man­aged to com­plete an IPO in the US, the worst record since the bad old days of 2012. And the smart mon­ey at Sil­i­con Val­ley Bank says you can ex­pect a re­peat, or maybe some­thing just slight­ly bet­ter, in the year ahead.

In oth­er words, if you had to sum­ma­rize SVB’s IPO pro­jec­tion for 2017, a shaky thumbs-up is about the best you’re go­ing to get. The con­ga line of 2014 and 2015 has dis­solved and shows no signs of re­form­ing any­time soon.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.